Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
13,253
archived clinical trials in
Arthritis

Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
Paducah, KY
Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
Paducah, KY
Click here to add this to my saved trials
Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
Dallas, TX
Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
Duncansville, PA
Study to Characterize the Local Duration of Exposure From FX006 in Patients With Osteoarthritis of the Knee
An Open-label, Single Administration Study to Characterize the Local Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis (OA) of the Knee
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
Canoga Park, CA
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
Canoga Park, CA
Click here to add this to my saved trials
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
San Diego, CA
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
Hialeah, FL
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
Hialeah, FL
Click here to add this to my saved trials
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/13/2017
Clinical Research Facility
mi
from
Duncansville, PA
Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee
An Open-label, Single Administration Study to Characterize the Systemic Pharmacokinetics and Local Extent and Duration of Exposure of Triamcinolone Acetonide From FX006 in Patients With Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/13/2017
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
Proof of Concept Study of PEMF (Pulsed Electromagnetic Field) Therapy in Subjects With Osteoarthritis of the Knee
A Multicenter, Open-Label, Single-Arm, Proof of Concept Study of Pulsed Electromagnetic Field (PEMF) Therapy to Evaluate Synovial Fluid Markers in Subjects With Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/13/2017
Colorado Orthopaedics
mi
from
Lone Tree, CO
Proof of Concept Study of PEMF (Pulsed Electromagnetic Field) Therapy in Subjects With Osteoarthritis of the Knee
A Multicenter, Open-Label, Single-Arm, Proof of Concept Study of Pulsed Electromagnetic Field (PEMF) Therapy to Evaluate Synovial Fluid Markers in Subjects With Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/13/2017
Colorado Orthopaedics
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Proof of Concept Study of PEMF (Pulsed Electromagnetic Field) Therapy in Subjects With Osteoarthritis of the Knee
A Multicenter, Open-Label, Single-Arm, Proof of Concept Study of Pulsed Electromagnetic Field (PEMF) Therapy to Evaluate Synovial Fluid Markers in Subjects With Osteoarthritis of the Knee
Status: Enrolling
Updated:  12/13/2017
Spokane Joint Replacement
mi
from
Spokane, WA
Proof of Concept Study of PEMF (Pulsed Electromagnetic Field) Therapy in Subjects With Osteoarthritis of the Knee
A Multicenter, Open-Label, Single-Arm, Proof of Concept Study of Pulsed Electromagnetic Field (PEMF) Therapy to Evaluate Synovial Fluid Markers in Subjects With Osteoarthritis of the Knee
Status: Enrolling
Updated: 12/13/2017
Spokane Joint Replacement
mi
from
Spokane, WA
Click here to add this to my saved trials
Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin
Effects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy Participants
Status: Enrolling
Updated:  12/13/2017
PPD Development, LP
mi
from
Austin, TX
Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin
Effects of Concomitant Administration of BMS-986195 on the Single-dose Pharmacokinetics of Methotrexate and Probe Substrates for Cytochrome P450 1A2, 2C8, 2C9, 2C19, 3A4, Organic Anion Transporter Polypeptide 1B1 and P-glycoprotein in Healthy Participants
Status: Enrolling
Updated: 12/13/2017
PPD Development, LP
mi
from
Austin, TX
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Glendale, AZ
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Glendale, AZ
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Phoenix, AZ
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Tucson, AZ
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Palo Alto, CA
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Upland, CA
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Upland, CA
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Danbury, CT
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Danbury, CT
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Trumbull, CT
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Trumbull, CT
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Lewes, DE
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Lewes, DE
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Boynton Beach, FL
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Orlando, FL
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Tamarac, FL
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Tamarac, FL
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Tampa, FL
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Boise, ID
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Boise, ID
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Indianapolis, IN
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Lansing, MI
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Freehold, NJ
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Freehold, NJ
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Albany, NY
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Albany, NY
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Hartsdale, NY
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Hartsdale, NY
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Rochester, NY
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Rochester, NY
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Tulsa, OK
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Bethlehem, PA
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Bethlehem, PA
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Philadelphia, PA
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Wyomissing, PA
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Wyomissing, PA
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Myrtle Beach, SC
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Nassau Bay, TX
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Nassau Bay, TX
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Webster, TX
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Webster, TX
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Chesapeake, VA
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Chesapeake, VA
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Kennewick, WA
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Kennewick, WA
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Vancouver, WA
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Vancouver, WA
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Franklin, WI
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Franklin, WI
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
mi
from
Buenos Aires,
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
mi
from
Buenos Aires,
Click here to add this to my saved trials
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated:  12/18/2017
Clinical Research Facility
mi
from
Saint Louis, MO
A Moderate to Severe Rheumatoid Arthritis Study
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients With Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
Status: Enrolling
Updated: 12/18/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Boehringer Ingelheim Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
205.452.01283 Boehringer Ingelheim Investigational Site
mi
from
Phoenix, AZ
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
205.452.01283 Boehringer Ingelheim Investigational Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1245.25.10015 Boehringer Ingelheim Investigational Site
mi
from
Little Rock, AR
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1245.25.10015 Boehringer Ingelheim Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1301.1.5765 Boehringer Ingelheim Investigational Site
mi
from
El Cajon, CA
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1301.1.5765 Boehringer Ingelheim Investigational Site
mi
from
El Cajon, CA
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1301.1.5553 Boehringer Ingelheim Investigational Site
mi
from
Lakewood, CA
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1301.1.5553 Boehringer Ingelheim Investigational Site
mi
from
Lakewood, CA
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
1199.14.1181 Boehringer Ingelheim Investigational Site
mi
from
Long Beach, CA
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
1199.14.1181 Boehringer Ingelheim Investigational Site
mi
from
Long Beach, CA
Click here to add this to my saved trials
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated:  12/19/2017
Boehringer Ingelheim Investigational Site
mi
from
San Diego, CA
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis
Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid Arthritis: an Open-label Extension Trial
Status: Enrolling
Updated: 12/19/2017
Boehringer Ingelheim Investigational Site
mi
from
San Diego, CA
Click here to add this to my saved trials